Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.

ABSTRACT:

Background

The present prospective study aimed at determining the impact of cell-free tumor DNA (ct-DNA), CA125 and HE4 from blood and ascites for quantification of tumor burden in patients with advanced high-grade serous epithelial ovarian cancer (EOC).

Methods

Genomic DNA was extracted from tumor FFPE and ct-DNA from plasma before surgery and on subsequent post-surgical days. Extracted DNA was subjected to hybrid-capture based next generation sequencing. Blood and ascites were sampled before surgery and on subsequent post-surgical days. 20 patients (10 undergoing complete resection (TR0), 10 undergoing incomplete resection (TR>0)) were included.

Results

The minor allele frequency (MAF) of TP53 mutations in ct-DNA of all patients with TR0 decreased significantly, com

SUBMITTER: Heitz F 

PROVIDER: S-EPMC8820624 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature